Sharun Khan, Tiwari Ruchi, Dhama Kuldeep
Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, Uttar Pradesh Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vigyan Vishwavidyalaya Evam Go Anusandhan Sansthan (DUVASU), Mathura, 281001, India.
Ann Med Surg (Lond). 2020 Dec 28;61:122-125. doi: 10.1016/j.amsu.2020.12.030. eCollection 2021 Jan.
The main protease (M) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important therapeutic target as it plays a major role in the processing and maturation of the viral polyprotein. GC376 is a pre-clinical dipeptide-based protease inhibitor that has been previously used for managing feline infectious peritonitis virus (FIPV). Since both GC373 and GC376 have already been successfully used in treating animal coronavirus infection, they can be considered as strong drug candidates for COVID-19 in humans. GC376 is a broad-spectrum antiviral drug that inhibits M of several viruses, including the coronaviruses like feline coronavirus, porcine epidemic diarrhoea virus, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, ferret, and mink coronavirus. However, further studies should be conducted to evaluate the potency, efficacy, and safety of these broad-spectrum M inhibitors in patients with COVID-19. The lessons learned from the successful use of drug candidates for treating animal coronavirus infections will help us to develop framework for their use in human trials.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的主要蛋白酶（M）是一个重要的治疗靶点，因为它在病毒多聚蛋白的加工和成熟过程中起主要作用。GC376是一种临床前基于二肽的蛋白酶抑制剂，此前已用于治疗猫传染性腹膜炎病毒（FIPV）。由于GC373和GC376都已成功用于治疗动物冠状病毒感染，它们可被视为治疗人类COVID-19的有力候选药物。GC376是一种广谱抗病毒药物，可抑制多种病毒的M蛋白酶，包括猫冠状病毒、猪流行性腹泻病毒、严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒、雪貂冠状病毒和水貂冠状病毒等冠状病毒。然而，应进一步开展研究，以评估这些广谱M蛋白酶抑制剂在COVID-19患者中的效力、疗效和安全性。从成功使用候选药物治疗动物冠状病毒感染中吸取的经验教训将有助于我们制定其在人体试验中的使用框架。
